Reduced NGF secretion by HT-29 human colon cancer cells treated with a GRPR antagonist.
The gastrin-releasing peptide receptor (GRPR) is a therapeutic target in colon cancer. Here we show that the GRPR antagonist RC-3095 (10(-3), 10(-6), or 1 microM) decreases nerve growth factor (NGF) secretion measured by enzyme-linked immunosorbent assay (ELISA) in HT-29 human colon carcinoma cells. The results suggest that decreased secretion of neurotrophins might be a novel mechanism by which GRPR antagonists exert their antiproliferative effects in cancer cells.
de Farias
Caroline Brunetto
CB
Cancer Research Laboratory, Academic Hospital Research Center, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil.
Stertz
Laura
L
Lima
Rodrigo Cruz
RC
Kapczinski
Flávio
F
Schwartsmann
Gilberto
G
Roesler
Rafael
R
D000704:Analysis of Variance; D001839:Bombesin / Q000031:analogs & derivatives* / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004797:Enzyme-Linked Immunosorbent Assay; D019073:HT29 Cells; D006801:Humans; D020932:Nerve Growth Factor / Q000378:metabolism*; D010446:Peptide Fragments / Q000494:pharmacology*; D018004:Receptors, Bombesin / Q000037:antagonists & inhibitors*
C502240:NGF protein, human; D010446:Peptide Fragments; D018004:Receptors, Bombesin; C071363:bombesin (6-14), Tpi(6)-Leu(13)-psi(CH2NH)-Leu(14)-; D020932:Nerve Growth Factor; D001839:Bombesin